Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To assess the spectrum and potency of ceftaroline, a novel anti-methicillin-resistant staphylococcal cephalosporin, against a 2008 surveillance collection of clinical isolates from patients in the USA and Europe. METHODS: A collection of 14 169 isolates of various bacterial species from complicated skin and skin structure infections (cSSSIs) was tested for susceptibility to ceftaroline and 19 comparator agents in a central reference laboratory using CLSI broth microdilution methods. Organisms were received from 55 medical centres; 27 in the USA and 28 in Europe (12 countries, including Israel). The clonality of isolates of Staphylococcus aureus with elevated ceftaroline MICs (4 mg/L) was determined by PFGE and single and multilocus sequence typing, and the mechanism of ceftaroline non-susceptibility was assessed by molecular methods (PCR amplification and sequencing). RESULTS: Ceftaroline, the active component of the parenteral prodrug ceftaroline fosamil, was active against 2988 methicillin-resistant S. aureus (MRSA) isolates, with an MI₉₀ of 1 mg/L. The MIC₉₀ for methicillin-susceptible strains was 0.25-0.5 mg/L. Ceftaroline was additionally active against coagulase-negative staphylococci (MIC₉₀, 0.5-1 mg/L), Enterococcus faecalis (MIC₅₀, 2 mg/L), β-haemolytic and viridans group streptococci (MIC₉₀, 0.015-0.25 mg/L) and three commonly isolated Enterobacteriaceae (Escherichia coli, Klebsiella spp. and Proteus mirabilis; MIC₉₀ values of 0.25 to > 16 mg/L). All but four isolates of MRSA (0.13%) had ceftaroline MIC values of ≤ 2 mg/L. The isolates for which ceftaroline MICs were 4 mg/L were clonal (single Greek hospital) and had detectable mecA mutations (N146K, N204K, E150K and H351N). CONCLUSIONS: The ceftaroline yearly (2008) surveillance for the USA and Europe documented low MIC₅₀/₉₀ values for MRSA isolates at 1/1 and 1/2 mg/L, respectively. Ceftaroline demonstrated promising potency and coverage against Gram-positive and -negative pathogens known to cause cSSSIs, including MRSA and β-haemolytic streptococci.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489
Cited by
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Penicillin‐binding protein 2a of methicillin‐resistant Staphylococcus aureus
Fishovitz, J., Hermoso, J. A., Chang, M., & Mobashery, S. (2014) · IUBMB Life · doi:10.1002/iub.1289 · Cited by 279
Lin, J. C., Fierer, J., Aung, G., Johns, S., Thomas, A., Jahng, M., Fierer, J., & Fierer, J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0449-9 · Cited by 109
Lee, H., Yoon, E.-J., Kim, D., Kim, J. W., Lee, K.-J., Kim, H. S., Kim, Y. R., Shin, J. H., Shin, J. H., Shin, K. S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-18 · Cited by 32
Metadata
- Authors
- Jones, R. N., Mendes, R. E., & Sader, H. S.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-01
- Volume
- 65
- Issue
- Supplement 4
- Pages
- iv17-iv31
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2154830968
- Cited by
- 90
- References
- 1
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.